Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
Shares float: 61.87M
Topline Data 16/10/2024 ET
Phase 2 topline data to be presented at ISPAD October 16-19, 2024. Phase 2 first patient dosed April 13, 2023. Phase 2 enrollment completed, noted February 8, 2024. Phase 2 data demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with disease progression, noted April 10, 2024.
2 more catalysts end of August 2025 and end of December 2025
Huge down gap from $18.00 to $4.50
Breakout and Entry Zone above: $2.60
Action: If the stock breaks above this area with strong volume, it might signal a continuation of the upward trend.
Overall Market Sentiment: Currently, the market seems to be in a correction phase. It’s crucial to consider this sentiment when making trading decisions.
Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains.
Trading Strategy:
Take Profit (TP): Set a target at $6.50 (pre catalyst run up) and if we see a full gap fill set a second one at $18.00 (highly speculative and could take time)
Stop Loss (SL): Set at under $1.70 to mitigate potential losses.
Chart Analysis: Please refer to the attached chart for detailed analysis of price trends and movements.
Trading Advisory: Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities.
Disclaimer: This content is for informational purposes only and should not be considered financial advice.
Nota
slow and steady - let's gooo
Nota
Amylyx Pharmaceuticals Shares Jump After Wolfram Syndrome Treatment Study Shows Improvement
Oct 17, 2024
Amylyx Pharmaceuticals Price Target Maintained With a 8.00/Share by HC Wainwright & Co.
Oct 18, 2024
boooom!
Dagangan aktif
its slowly pushing higher
recent passive stakes:
25/10/2024
Amylyx Pharmaceuticals, Inc. Passive Stake (FormSC13G) by PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD
4/11/2024
Amylyx Pharmaceuticals, Inc. Passive Stake (FormSC13G) by The Vanguard Group
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.